IDEXX Laboratories, Inc. (IDXX)

In the past six months, IDEXX's stock price has experienced fluctuations. As of July 14, 2025, the share price was $531.42, an increase of 10.09% from July 15, 2024. Key events impacting the stock include the Q1 2025 earnings report, which exceeded expectations and led to a surge in the stock price, new product launches such as the IDEXX inVue Dx Cellular Analyzer, analyst revisions with upward revenue expectations for FY2025, and share repurchases with plans to repurchase approximately $1.5 billion worth of shares in 2025.

Demand for IDEXX's products and services can exhibit seasonality, with sales of canine vector-borne disease tests typically greater in the first half of the fiscal year. Historically, the warm-weather months tend to offer the most favorable seasonality for vet visits. Despite factors such as labor pressure and inflationary pressure, IDEXX's free cash flow in Q1 2025 reflected "normal seasonality". The company anticipates continued growth, with demand for its offerings expected to rise as pet ownership increases and the focus on livestock and poultry health intensifies.

IDEXX Laboratories, Inc. is a multinational corporation focused on developing, manufacturing, and distributing products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. The company operates in the Healthcare sector, specifically in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. Its core business revolves around three main segments: Companion Animal Group (CAG), which provides diagnostic capabilities and information management solutions; Water Quality Products (Water), which provides testing solutions for water quality and safety; and Livestock, Poultry and Dairy (LPD), which offers diagnostic tests and services to manage the health status of livestock and poultry.

IDEXX Laboratories has a significant global presence, offering products to customers in over 175 countries. The company's principal regions for its Companion Animal Group products and services are the United States, Europe, Japan, China, and Australia. For its Water segment, the principal regions are the U.S. and Europe. The Livestock, Poultry and Dairy segment's principal regions are Europe, China, and Australia. IDEXX maintains a sales presence in major regions worldwide, including Africa, Asia Pacific, Canada, Europe, and Latin America. Its corporate headquarters are in Westbrook, Maine, U.S., with European headquarters in Hoofddorp, Netherlands.

IDEXX has a strong brand reputation for quality and reliability, built over decades of serving the veterinary healthcare market. The company is recognized as a market leader in veterinary diagnostics, driven by its commitment to innovation and quality. No specific negative events significantly impacting IDEXX Laboratories, Inc.'s brand reputation in the past year were found in the provided search results.

IDEXX Laboratories, Inc. is largely controlled by institutional shareholders, who own approximately 88% of the company. Individual investors hold about 11% ownership, and insiders own under 1% of the company. The largest institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp.